Your browser doesn't support javascript.
loading
Control of Mycobacterial Infections in Mice Expressing Human Tumor Necrosis Factor (TNF) but Not Mouse TNF.
Olleros, Maria L; Chavez-Galan, Leslie; Segueni, Noria; Bourigault, Marie L; Vesin, Dominique; Kruglov, Andrey A; Drutskaya, Marina S; Bisig, Ruth; Ehlers, Stefan; Aly, Sahar; Walter, Kerstin; Kuprash, Dmitry V; Chouchkova, Miliana; Kozlov, Sergei V; Erard, François; Ryffel, Bernard; Quesniaux, Valérie F J; Nedospasov, Sergei A; Garcia, Irene.
Affiliation
  • Olleros ML; Department of Pathology and Immunology, CMU, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Chavez-Galan L; Department of Pathology and Immunology, CMU, Faculty of Medicine, University of Geneva, Geneva, Switzerland Laboratory of Integrative Immunology, National Institute of Respiratory Diseases, Mexico City, Mexico.
  • Segueni N; University of Orleans and CNRS, UMR7355, and Experimental and Molecular Immunology and Neurogenetics, Orleans, France.
  • Bourigault ML; University of Orleans and CNRS, UMR7355, and Experimental and Molecular Immunology and Neurogenetics, Orleans, France.
  • Vesin D; Department of Pathology and Immunology, CMU, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Kruglov AA; Belozersky Institute of Physico-Chemical Biology and Biological Faculty, Lomonosov Moscow State University, Moscow, Russia German Rheumatism Research Center (DRFZ), a Leibniz Institute, Berlin, Germany Laboratory of Experimental Immunology, Lobachevsky State University of Nizhni Novgorod, Nizhni Nov
  • Drutskaya MS; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
  • Bisig R; Department of Pathology and Immunology, CMU, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Ehlers S; Priority Research Area Infections, Research Center Borstel, Borstel, Germany.
  • Aly S; Priority Research Area Infections, Research Center Borstel, Borstel, Germany.
  • Walter K; German Center for Infection Research, Thematic Translational Unit Tuberculosis, Braunschweig, Germany.
  • Kuprash DV; Laboratory of Experimental Immunology, Lobachevsky State University of Nizhni Novgorod, Nizhni Novgorod, Russia Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
  • Chouchkova M; BulBio-National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.
  • Kozlov SV; Center for Advanced Preclinical Research, Laboratory Animal Sciences Program, Leidos Biomed, Inc., Frederick, Maryland, USA.
  • Erard F; University of Orleans and CNRS, UMR7355, and Experimental and Molecular Immunology and Neurogenetics, Orleans, France.
  • Ryffel B; University of Orleans and CNRS, UMR7355, and Experimental and Molecular Immunology and Neurogenetics, Orleans, France.
  • Quesniaux VF; University of Orleans and CNRS, UMR7355, and Experimental and Molecular Immunology and Neurogenetics, Orleans, France.
  • Nedospasov SA; Belozersky Institute of Physico-Chemical Biology and Biological Faculty, Lomonosov Moscow State University, Moscow, Russia German Rheumatism Research Center (DRFZ), a Leibniz Institute, Berlin, Germany Laboratory of Experimental Immunology, Lobachevsky State University of Nizhni Novgorod, Nizhni Nov
  • Garcia I; Department of Pathology and Immunology, CMU, Faculty of Medicine, University of Geneva, Geneva, Switzerland Irene.garcia-gabay@unige.ch.
Infect Immun ; 83(9): 3612-23, 2015 Sep.
Article in En | MEDLINE | ID: mdl-26123801
ABSTRACT
Tumor necrosis factor (TNF) is an important cytokine for host defense against pathogens but is also associated with the development of human immunopathologies. TNF blockade effectively ameliorates many chronic inflammatory conditions but compromises host immunity to tuberculosis. The search for novel, more specific human TNF blockers requires the development of a reliable animal model. We used a novel mouse model with complete replacement of the mouse TNF gene by its human ortholog (human TNF [huTNF] knock-in [KI] mice) to determine resistance to Mycobacterium bovis BCG and M. tuberculosis infections and to investigate whether TNF inhibitors in clinical use reduce host immunity. Our results show that macrophages from huTNF KI mice responded to BCG and lipopolysaccharide similarly to wild-type macrophages by NF-κB activation and cytokine production. While TNF-deficient mice rapidly succumbed to mycobacterial infection, huTNF KI mice survived, controlling the bacterial burden and activating bactericidal mechanisms. Administration of TNF-neutralizing biologics disrupted the control of mycobacterial infection in huTNF KI mice, leading to an increased bacterial burden and hyperinflammation. Thus, our findings demonstrate that human TNF can functionally replace murine TNF in vivo, providing mycobacterial resistance that could be compromised by TNF neutralization. This new animal model will be helpful for the testing of specific biologics neutralizing human TNF.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Necrosis Factor-alpha / Disease Models, Animal / Mycobacterium Infections Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Infect Immun Year: 2015 Type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Necrosis Factor-alpha / Disease Models, Animal / Mycobacterium Infections Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Infect Immun Year: 2015 Type: Article Affiliation country: Switzerland